Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Non-selective NSAID

Indometacin

Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation in conditions such as acute gout, rheumatoid arthritis and other musculoskeletal disorders.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It non-selectively inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis to produce analgesic, anti-inflammatory and antipyretic effects.

Prescribing in practice

  • Like other NSAIDs it carries gastrointestinal bleeding, cardiovascular and renal risks, so use the lowest effective dose for the shortest time and consider gastroprotection in those at risk.
  • It is relatively poorly tolerated, with a high incidence of central nervous system effects such as headache and dizziness compared with other NSAIDs.
  • Avoid in active peptic ulceration, severe heart failure and significant renal impairment, and use caution with anticoagulants and other nephrotoxic drugs.

Monitoring

Monitor blood pressure, renal function and for gastrointestinal symptoms, particularly in older or higher-risk patients.

Counselling the patient

  • Take with or after food and report indigestion, black stools or signs of bleeding.
  • Report headache, dizziness or visual disturbance, which can occur with this medicine.
  • Avoid other NSAIDs, including over-the-counter products, unless advised.

Evidence & guidelines

NSAID cardiovascular and gastrointestinal risks are highlighted in MHRA advice and NICE guidance on prescribing.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways